Parvus Therapeutics, Inc.

This early-stage study tests a new drug called PVT401 in 36 healthy volunteers to see if it is safe and how the body handles it. Participants receive either the drug or a placebo by IV, either as a single dose or multiple doses over five weeks. The goal is to gather safety data b…